Physician profile
Steve E Herndon
NPI 1861516668
$10,795.99
in general payments reported to CMS, 2019-2025
39 companies · $2,461 in 2025
The $2,461 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $172 · 2021: $1,254 · 2022: $2,329 · 2023: $2,113 · 2024: $2,282 · 2025: $2,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,839 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,839.29 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,204.42 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,235.30 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $753.73 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $690.94 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $641.53 | 2019-2025 | Dupixent |
| Genzyme Corporation | $597.09 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $518.56 | 2021-2025 | Acthar |
| United Therapeutics Corporation | $479.30 | 2022-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $397.56 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $393.67 | 2020-2025 | Opsumit, Uptravi, Opsynvi |
| Mylan Specialty L.P. | $341.60 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $307.05 | 2021-2025 | Winrevair, Zerbaxa, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $298.68 | 2023-2025 | Glassia, Hyqvia |
| Jazz Pharmaceuticals INC. | $259.45 | 2019-2025 | Xywav |
| Verona Pharma, INC. | $214.28 | 2025 | Ohtuvayre |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $199.48 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Axsome Therapeutics, INC. | $151.38 | 2023-2025 | Sunosi |
| Electromed, INC. | $142.73 | 2022-2023 | Smartvest |
| Abbvie INC. | $133.86 | 2021-2022 | |
| Genentech USA, INC. | $119.00 | 2022-2023 | Xolair |
| Harmony Biosciences LLC | $111.73 | 2021-2025 | Wakix |
| Philips North America LLC | $106.98 | 2022-2025 | Vest Therapy Und |
| Avadel Cns Pharmaceuticals, LLC | $75.26 | 2024-2025 | Lumryz |
| Grifols USA, LLC | $52.20 | 2021-2024 | Xembify |
| Advanced Respiratory, INC | $49.89 | 2020-2021 | |
| Viatris Specialty LLC | $35.62 | 2025 | Yupelri |
| Ethicon INC. | $31.21 | 2025 | Monarch Platform |
| Optinose US, INC. | $29.34 | 2021 | |
| Eisai INC. | $27.65 | 2021 | |
| Ani Pharmaceuticals, INC. | $25.77 | 2024 | Purified Cortrophin Gel |
| Apria Healthcare LLC | $25.14 | 2021 | |
| Resmed Corp | $23.73 | 2021 | |
| Lilly USA, LLC | $22.36 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $21.10 | 2023 | |
| Intuitive Surgical, INC. | $20.43 | 2021 | |
| Gilead Sciences, INC. | $16.65 | 2023 | |
| Inari Medical, INC. | $16.26 | 2022 | |
| Novo Nordisk INC | $13.66 | 2019 | |
| Ambu INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Herndon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.